Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $8.82, for a total transaction of $17,640.00. Following the sale, the chief executive officer now owns 14,615,662 shares in the company, valued at $128,910,138.84. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Thomas Sandgaard also recently made the following trade(s):

• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Stock Up 10.2 %

Shares of NASDAQ ZYXI opened at $9.21 on Thursday. The firm’s 50-day moving average is $8.14 and its two-hundred day moving average is $9.00. The company has a market capitalization of $293.30 million, a PE ratio of 61.40 and a beta of 0.53. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. Zynex’s revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. Equities analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada lowered their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright raised their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th.

Institutional Trading of Zynex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gladius Capital Management LP lifted its holdings in Zynex by 53.4% in the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after purchasing an additional 1,742 shares in the last quarter. Royce & Associates LP raised its position in shares of Zynex by 9.2% in the third quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock valued at $2,099,000 after buying an additional 21,781 shares during the last quarter. GSA Capital Partners LLP lifted its stake in shares of Zynex by 72.7% during the third quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after buying an additional 33,649 shares during the period. Janney Montgomery Scott LLC boosted its position in Zynex by 22.3% during the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock worth $1,179,000 after acquiring an additional 26,368 shares during the last quarter. Finally, Investment Partners Asset Management Inc. purchased a new stake in Zynex in the 3rd quarter worth approximately $96,000. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.